The Readout Loud
346: Zealand's obesity strategy and Immunovant's curious development plan
Mar 20, 2025
Adam Steensberg, CEO of Zealand Pharma, shares insights on his company’s innovative amylin-targeting obesity treatment and its strategic partnership with Roche, valued at $1.65 billion. He challenges industry norms by emphasizing sustainable weight loss over drastic changes. Robert Salcedo, CEO of OceanBio, discusses the unique biotech landscape in Puerto Rico, focusing on advancements in gene therapies and the potential for affordable medicine production. Together, they highlight the shifting priorities in obesity treatment and the resilient future of biotech in Puerto Rico.
42:34
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Zealand Pharma’s CEO highlights their innovative obesity treatment, Petrolintide, and the strategic partnership with Roche aimed at enhancing manufacturing capabilities.
- The podcast discusses a tragic patient death linked to gene therapy, raising critical concerns about regulatory standards and safety for vulnerable populations.
Deep dives
Biotech Manufacturing in Puerto Rico
Puerto Rico is emerging as a crucial hub for the biopharmaceutical industry, offering advantages like advanced facilities and access to a skilled talent pool. Companies like OceanBio are developing infrastructure to support new therapies and biotechnological advancements. The island's unique combination of bilingual capabilities and competitive incentives makes it attractive for companies looking to establish operations. This strategic positioning supports the rapid growth and development of the biotech sector in an increasingly competitive landscape.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
